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Receptor agonism remains poorly understood at the molecular and mechanistic level. In this study, we identiﬁed a fully human
anti-Fas antibody that could efﬁciently trigger apoptosis and therefore function as a potent agonist. Protein engineering and
crystallography were used to mechanistically understand the agonistic activity of the antibody. The crystal structure of the
complex was determined at 1.9A ˚ resolution and provided insights into epitope recognition and comparisons with the natural
ligand FasL (Fas ligand). When we afﬁnity-matured the agonist antibody, we observed that, surprisingly, the higher-afﬁnity
antibodies demonstrated a signiﬁcant reduction, rather than an increase, in agonist activity at the Fas receptor. We propose and
experimentallydemonstrateamodeltoexplain thisnon-intuitiveimpact ofafﬁnityonagonistantibodysignallingandexplorethe
implications for the discovery of therapeutic agonists in general.
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Receptor agonism is a key step in the transmission of signals
from the outside to the inside of a cell. Despite many years of
study, the precise mechanisms underlying ligand-mediated
agonism of cell surface receptors remain poorly understood.
Indeed, if one takes the well-studied T-cell receptor as an
example, a recent review
1 highlights that three competing
theories, namely receptor aggregation, conformational
change and segregation of receptors from intracellular
inhibitors, are all supported by experimental data and may
all be partly responsible for signal transduction.
An important group of agonistic receptors is the tumour
necrosis factor (TNF) receptor superfamily, members of
which are known to form trimeric signalling complexes upon
ligation with their cognate trimeric ligands.
2 As many TNF
receptor superfamily members have signiﬁcant roles in
the progression of human disease,
3 a better understanding
of their signalling mechanisms could enable the design
of potent agonist and antagonist molecules as candidate
drugs for clinical development. Monoclonal antibodies,
with their high afﬁnity, target selectivity and long serum half-
lives, are well suited as receptor agonist drug molecules.
Accordingly, there are agonistic antibodies in preclinical and
clinical development against several TNF receptor family
members, such as TNF-related apoptosis inducing ligand
(TRAIL) receptor 1,
4 TRAIL receptor 2,
5 glucocorticoid-
induced tumor necrosis factor receptor (GITR),
6 CD137
7
and CD40.
8
The TNF receptor superfamily member Fas (CD95, APO-1,
TNFRSF6) is a receptor, which participates in signal
transduction to trigger cellular apoptosis after binding to Fas
ligand (FasL).
9 Because of its expression on many tumours
and its ability to trigger apoptosis,
10 Fas could be considered
aninterestingtargetfortherapeuticintervention.However,the
ﬁnding that an agonistic Fas antibody administered to mice
caused severe liver damage and rapid death has led to the
conclusion that Fas is not a valid therapeutic target.
11 Despite
the possible limitations of Fas in the therapeutic setting it can
still be considered a relevant model system to explore the
nature of agonistic antibody signalling in the TNF receptor
superfamily. Agonistic antibodies, as opposed to the more
frequently isolated antagonistic or neutralising antibodies,
have rarely been studied from a structure–function perspec-
tive and little is known about the importance of epitope and
afﬁnity in the biological potency of such antibodies. Whereas
neutralisingantibodiesareexpectedtoexhibitadirectpositive
correlation between afﬁnity and potency, agonist antibodies
are potentially more subtleand difﬁculttounderstand and asa
consequence it could be more challenging to enhance their
potency.
In this study, phage-display technology was used to identify
a human anti-Fas antibody, which could efﬁciently trigger
apoptosis and therefore demonstrate potent in vitro tumour
cell-killing activity. This model agonistic antibody was then
used as a starting point for mutational and crystallographic
studies to explore the binding interface and better understand
the agonistic activity. This systematic analysis of an agonistic
antibody interacting with its receptor, in particular the
exploration of the relationship between afﬁnity and potency,
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agonistic antibody signalling.
Results
Isolation of agonistic anti-Fas antibody E09 and
comparison with other agonists. Antibodies to human
Fas receptor were isolated by performing phage-display
selections
12 on the recombinant extracellular domain (ECD)
of Fas. Antibodies speciﬁc for Fas ECD were detected by
phage ELISA and a total of 264 unique scFv were
sequenced. Of the 264 different scFv antibodies screened
for agonism in a cell-viability assay, only one was identiﬁed
as having anti-proliferative activity. This scFv, E09, was
converted to human IgG1 antibody format for further
characterisation. To conﬁrm the agonistic activity towards
the human Fas receptor, assays were performed on Jurkat
cells to measure caspase 3/7 activation and DNA
fragmentation, which, respectively, are early and late
readouts for apoptosis. The E09 antibody was compared
with the natural ligand FasL in recombinant form and two
agonistic anti-Fas antibodies, the mouse monoclonal
antibodies DX2 and SM1.1.
10,13 All agonists were able to
induce caspase 3/7 activity and DNA fragmentation, as
shown in Figure 1, but to differing extents. E09 was as potent
as the natural ligand FasL at triggering caspase 3/7 activity
and even more potent than FasL at inducing DNA
fragmentation with an EC50 of 0.7 and 2.8nM for E09 and
FasL, respectively.
In a Jurkat cell-viability assay, two parameters could be
determined. Efﬁciency was deﬁned as the maximal cell killing
(in percentage) that could be obtained and EC50 as the molar
concentration of agonist required to obtain half-maximal
killing. E09 demonstrated an efﬁciency of 80% (Table 1),
which is slightly lower than FasL (94%) but had a signiﬁcantly
lower EC50 than the natural ligand (0.9nM and 7nM for E09
and FasL, respectively). The other agonist antibodies DX2
and SM1.1 showed reduced cell-killing efﬁciencies, of 16%
and 26% respectively (Table 1). As the agonistic anti-Fas
antibodies exhibited different apoptotic potencies, we ex-
plored the possible reasons.
Does the efﬁcacy depend on the afﬁnity or epitope? The
ﬁrst obvious cause for a difference in agonism could
be a difference in the afﬁnity, as previously proposed.
14
Therefore, we determined the dissociation constants of
the complexes between the human Fas ECD and each
agonist by surface plasmon resonance (SPR). The Kd values
of all antibodies were in the range between 5 and 17nM
(Table 1) and therefore similar to each other and to
human FasL (14nM). This suggested that the difference
in biological activity between the agonists was not simply
due to different afﬁnities for the receptor. As an alternative
explanation, we considered whether the epitope might have
a potential impact on the agonism and performed a
competition assay with the different agonists. All antibodies
totally competed the FasL:Fas interaction with similar IC50
values, suggesting that the antibodies could be functioning
as ligand mimetics (Table 1). However, the three agonistic
antibodies did not all compete with each other for a single
binding epitope. Although antibody SM1.1 was able to
completely inhibit the E09:Fas interaction, antibody DX2
showed only partial competition for Fas binding. These
results imply that, although all of the antibodies compete with
the natural ligand FasL, there is not a single binding site on
the receptor, which is critical for agonism. It should be noted
that epitope competition assays only offer an approximate
mapping of binding epitopes rather than any precise level of
molecular detail.
Molecular details revealed by the structure of Fas ECD in
complex with E09 Fab. To gain further insight into the
interaction of E09 with Fas, we determined the structure of
the complex by X-ray crystallography of the Fab fragment of
antibody E09 in complex with Fas ECD. The crystals of the
complex diffracted to 1.9A ˚ resolution in the space group
C2221 (Supplementary Table 1). The solved structure
showed that Fab E09 bound to cysteine-rich domain (CRD)
1 and 2 from Fas receptor, burying 1030A ˚ 2 of accessible
surface on the receptor and 890A ˚ 2 on the variable domain of
both heavy and light chains (Figure 2a, Supplementary
Figure 1 and Supplementary Table 2). The epitope on Fas
was formed by a continuous surface patch spanning the
Figure 1 Analysis of antibody E09 agonism of Fas by comparison to other agonists. Jurkat cells were incubated for 8h with the indicated IgGs or FasL at different
concentrations. CAT002 was an unrelated IgG negative control. (a) The turnover of the effector caspase substrate z-DEVD-aminoluciferin was measured in relation to the
concentration of each agonist or control antibody. (b) The amount of oligonucleosomes present in the cytosol, an indicator of DNA fragmentation during apoptosis, was
detectedbyanantibody-basedassayandplottedversustheconcentration.Allexperimentswereperformedintriplicateanderrorbarsindicatethestandarddeviationbetween
replicates
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Cell Death and Differentiationoutermost tip of the molecule on CRD1 (Fas_58-61) and
reaching the last residue of CRD2 (Fas_86).
The antibody binding epitopeon Fas overlaps only little with
the predicted binding epitope for FasL, which is located on
CRD2 and CRD3 of Fas.
15 Of those residues, which are
crucial for FasL binding,
16 only two residues are found in the
antibody epitope, namely Fas_81F and Fas_86R. Fas_86R
waspreviouslydeemedessentialforbindingtoFasL,whereas
mutation of Fas_81F reduced binding.
17 We modelled FasL
and positioned it onto our structure of the complex according
to the positions death ligands usually take when interacting
with their cognate receptor (Figure 2b). In this model only one
loop of FasL overlaps with a loop of the agonistic antibody
(Figure 2c). This loop (the DE loop) harbours the highly
conserved XYP motif important for the interaction between
death ligands and their receptors.
18 The tyrosine of this
conserved motif (FasL Y218) overlaps with VH Y100d of the
antibody E09 (Figure 2c) and was even predicted to interact
directly with Fas receptor residue FasR86.
18 Interestingly, in
Fas:E09 Fas R86 of the receptor also interacts with the
overlapping tyrosine residue VH Y100d and stacks with its
guanidinium group on top of the aromatic side chain, thereby
forming a cation-p-interaction (Figure 2c and Supplementary
Figure 1). To understand whether VH Y100d really had a
crucial role in the E09 bioactivity, we mutated this position to
an arginine, which was shown to have a deleterious effect on
apoptosis induction in the context of FasL.
18 However, in the
context of the E09 antibody this mutant did not reduce
apoptosis induction (data not shown).
In a comparative analysis of known epitopes of agonistic
antibodiesinthedeathreceptorfamilywefoundthat,similarto
FasL, the other natural ligands interact mostly with CRD2 and
Table 1 Summary of binding afﬁnity, epitope competition and in vitro cell-killing
data for Fas agonists
Competition
with FasL
Competition
with E09 IgG
Jurkat cell
killing
Ligand
Fas Kd,
nM
IC50,
nM
Max.
Inh., %
IC50,
nM
Max.
Inh., %
EC50,
nM
Efﬁciency,
%
FasL 14.0 ND ND ND ND 7.1 94.0
E09 17.0 1.4 100.0 0.9 100.0 0.9 80.0
DX2 7.3 2.4 98.0 1.6 34.0 1.4 16.0
SM1.1 5.2 5.5 86.0 1.8 100.0 4.0 26.0
The Kd values were determined bySPR analysis ofbinding to recombinant Fas.
Each antibody was also tested for their ability to compete the Fas:FasL and the
Fas:E09 interactions in biochemical competition assays to calculate an IC50
value (nM) and maximum inhibition value (%). Cell viability assays were
performed on Jurkat cells using a titration of anti-Fas molecules to determine
the maximal killing efﬁciency (%) and EC50 (nM)
Figure2 StructuralanalysisofFasagonistantibodyE09.(a)ThestructureofFasECDincomplexwithE09Fab.FasECDisrepresentedwithasurfacerenderingandthe
epitope on CRD1 and CRD2 coloured in darker blue and lighter blue, respectively. The E09 is shown as a cartoon with the heavy chain in darker green and the light chain in
lighter green. The CRD1, 2 and 3 are coloured in light pink, dark pink and red, respectively. (b) Model of a trimeric Fas-FasL complex that shows the binding of E09 in green
andFasLincyanintopview.(c)ArepresentationofFasECDincomplexwithE09FabinwhichtheepitopeoverlapbetweenFasLandE09isvisible.AsingletyrosineinFasL
(Y218) or E09 (VH_100d) makes contact with Fas_R86 (zoom). (d) Comparative analysis of broad epitopes on death receptors covered by natural ligands and agonistic
antibodies
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Cell Death and DifferentiationCRD3 of the death receptors (Figure 2d). In addition, the
agonistic anti-Fas CH-11 IgM antibody and anti-TRAIL
receptor 2 IgG antibody Apomab recognise this region of
the death receptors,
14,19 whereas anti-DR5 BDF2 and our
antibody anti-Fas E09 rather bind to CRD1 and CRD2.
20
There was generally a tendency for agonistic antibodies to
bind to the outside of the trimeric receptor, as opposed to the
natural ligands, which bound inside the trimer. From all these
observations we can infer that E09’s binding mode does not
correlate well with the natural ligand recognition site on Fas,
and that there is likely to be a different mechanism involved.
Afﬁnity maturation of anti-Fas E09 antibody. To under-
stand the agonistic mechanism, we attempted to improve
the biological activity of E09 by increasing the afﬁnity
for Fas. Six rounds of ribosome-display selections were
performed on a library of randomly mutated E09 variants
and the 44 variants with the highest afﬁnity from each
round were identiﬁed using an afﬁnity-based screen.
21
These scFv were puriﬁed and then re-analysed with
the same afﬁnity assay to demonstrate the effectiveness
of the evolution process in enriching for higher-afﬁnity
variants (Figure 3a).
Four variants with a range of afﬁnities for Fas were
converted to human IgG1 format for more precise afﬁnity
determination by SPR. The sequences of these variants are
shown in Supplementary Figure 2. The highest afﬁnity variant
EP6b_B01 had a Kd for monomeric human Fas of 350 pM and
was improved 49-fold compared with the parent antibody E09
(Table2).TheafﬁnityimprovementofEP6b_B01wasduetoa
faster on-rate (3.4-fold) and slower off-rate (14-fold), com-
pared with E09.
The sequence of EP6b_B01 contained seven amino-acid
substitutions from E09. Six of them were present in over 40%
ofvariantsintheafﬁnity maturedpopulationatselectionround
six, and were thus classiﬁed as hot-spot mutations (Supple-
mentary Figure 3). To quantify the energetic contribution of
the mutations, each was individually added to the E09
Figure 3 Directed evolutionof Fas antibodyE09. (a) Analysis of the 44 highest afﬁnity E09 variantantibodies from the six selection rounds, R1-R6. Surrogate afﬁnity was
determined using a six-point antigen titration in an ELISA-based assay. (b) Individual energy contribution of the seven mutations in the top clone EP6b_B01 to afﬁnity
improvement. Free energy of binding compared with the parent (DDG
0 (mut-WT)) of single-point mutants and revertants in the EP6b_B01 sequence context are shown in
white and grey, respectively. Theoretical additive values of the point mutant and the revertant are shown in dashed black. Energy calculations were based on BIAcore afﬁnity
measurement of scFvs for recombinant Fas. (c) Structural basis for afﬁnity improvement in EP6b_B01. The lower panels show close-up views from the squares in the upper
panel.TheleftpartofeachpanelshowsthezoomfromthestructureFasR:E09complex,therightpartthezoomfromFasR:EP6b_B01.Hydrogenbondsareindicatedasblack
dashed lines
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Cell Death and Differentiationbackbone or removed from EP6b_B01. Energetic analysis
was performed as before,
21 following afﬁnity measurements
(Supplementary Table 3). Three of the seven mutations, VH
T73S, VL Y50S and VL N51D, were shown to have a clear
beneﬁcial effect on afﬁnity (Figure 3b). The other single
mutations had no impact on afﬁnity despite the fact that three
of them were deﬁned as hotspots and were strongly selected
during the ribosome-display process.
The increased afﬁnity of EP6b_B01 towards Fas ECD was
analysed by structural means. The complex of Fas ECD with
Fab EP6b_B01 crystallised in the space group P3121 and the
structure was solved at 2.1A ˚ resolution. EP6b_B01 covered
the same epitope on Fas as its parent antibody E09. Analysis
of the interface revealed that the number of hydrogen bonds
increasedbyafactoroftwoandelectrostaticinteractionswere
introduced. The energetically relevant VL S50 and VL D51
indeed appeared to be key residues in these extended
interactions (Figure 3c, lower left panel). Vernier residue VH
73 contributes to the increased afﬁnity by a rearrangement of
the CDRs, thereby allowing VH S33 to form an additional
hydrogen bond with Fas Q41 (Figure 3c, lower right panel).
Linking afﬁnity and biological activity of anti-Fas
antibodies. Four selected IgG variants exhibiting a range
of afﬁnities for Fas receptor were then characterised for their
apoptotic activity. The in vitro viability assay using Jurkat
cells demonstrated a surprising negative correlation
between Fas afﬁnity and cell-killing efﬁciency (Figure 4a
and Supplementary Table 4). For instance, E09 and the
intermediate afﬁnity-optimised variant EP5b_E05 showed
efﬁciencies of 75% and 43% respectively. Most signiﬁcantly,
the highest afﬁnity antibody EP6b_B01 did not show activity
at all.
To conﬁrm that this result was not just an artefact of the
ribosome display directed evolution process, rational point
mutants of E09 were generated to modulate the afﬁnity for
Fas. By randomising six contact residues in E09 and screen-
ing the variants, antibodies with improved afﬁnity could be
isolated (Supplementary Figure 4), primarily by targeting VH
Y52a and VH R52b. Mutations at those positions were not
seen during the ribosome-display process and, when tested
for agonism, these point mutants also exhibited an inverse
correlation between afﬁnity and biological activity (Supple-
mentary Table 4).
In all cases, the increase of afﬁnity for the matured
antibodies, whether derived by directed evolution or rational
point mutagenesis, was due to a decrease in the off rate
(Table 2). Furthermore, the off rates of the E09 antibody and
variants, when plotted against cell-killing efﬁciency
(Figure 4b), showed a good correlation (r
2 value of 0.92).
Kinetic analysis of Fas agonism. As the E09 antibody and
its variants were assumed to all bind a similar epitope on Fas,
based on their similar sequences and also the elucidation of
near identical epitopes in the E09:Fas and EP6b_B01:Fas
crystal structures, the main difference between the variants
Table 2 Fas binding kinetics of E09 and variant antibodies
IgG name Optimisation method kon,M
 1s
 1 koff,s
 1 Kd,n M Kd gain vs parent
E09 (Parent antibody) 1.9E+05 3.2E-03 17 1
EP12r_E01 Directed Evolution 1.8E+05 1.8E-03 10 2
EP4b_E03 Directed Evolution 2.2E+05 6.4E-04 2.9 6
EP5b_E05 Directed Evolution 3.4E+05 3.1E-04 0.91 19
EP6b_B01 Directed Evolution 6.4E+05 2.3E-04 0.35 49
E09_Y58W Point Mutation 1.7E+05 1.7E-02 98 0
E09_Y52aR Point Mutation 1.7E+05 8.2E-03 47 0
E09_R52bS Point Mutation 1.5E+05 3.5E-04 2.4 7
Values for kon, koff and Kd were calculated following SPR analysis of binding to recombinant Fas. The Kd gain of each variant relative to the parent antibody E09 was
also calculated
Figure4 E09variantswithhigherafﬁnityarelesspotentagonists.(a)Dose-dependentkillingofJurkatcellsbyE09parentantibody,afﬁnityoptimisedvariants,ornegative
control CAT002. Dose response curves were plotted from cell-viability data following treatment with each of the antibodies. The cell-viability assay was performed in
quadruplicate and error bars indicate the S.D. between replicates. The afﬁnity of each antibody for Fas is also labelled next to the relevant curve. (b) The rate of koff (s
 1) for
E09andvariantantibodies,asdeterminedbySPR,wasplottedagainsttheJurkatcell-killingefﬁciency.TheparentantibodyE09isindicatedbyacirclecontainingacross,the
directed evolution variants are shown as unﬁlled circles and point mutants are shown as ﬁlled circles
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Cell Death and Differentiationwas their altered binding kinetics. To explore whether
the different binding kinetics could be affecting agonism,
a time-course experiment was performed with FasL, E09 and
the variant antibodies, measuring the rate of caspase 3/7
activation in Jurkat cells. FasL initiated caspase 3/7 activity
in Jurkat cells more rapidly than any of the ﬁve tested
IgGs (Figure 5a). The antibodies with faster off rates, such
as E09 or EP4b_E03, were able to trigger the cascade
more rapidly than antibodies EP5b_E05, E09_R52bS and
EP6b_B01, which demonstrated slower off rates. Such
results were in accordance with the cell-killing efﬁciency
data (Figure 4).
On the basis of the previous observations that an increased
avidity of anti-death receptor antibodies improved the
bioactivity tremendously,
20,22 we investigated the effect of
cross-linking on a selection of our previously characterised
IgGs. We used the pentavalent recombinant protein A to
cross-link the antibodies via their Fc domains and evaluated
the rate at which the Fas agonists could trigger caspase
activation. The trimeric recombinant FasL was again used as
a positive control for a rapid induction of apoptosis.
With protein A cross-linking, caspase activation was
accelerated even beyond FasL, for the majority of agonist
antibodies (Figure 5b). Interestingly, cross-linking enhanced
the speed of caspase activation of all antibodies indepen-
dentlyoftheirFasafﬁnitiesoroffrates,resultinginverysimilar
kinetic proﬁles for all variants, except EP6b_B01. In addition,
the cell-killing efﬁciency and EC50 of the IgGs improved upon
cross-linking (Supplementary Figure 5). For example, the
efﬁciencyandEC50ofE09IgGimprovedfrom69.4%to88.5%
and from 0.83nM to 0.10nM, respectively.
On the basis of our ﬁndings, we propose a model in which
partial dissociation of a bivalent antibody from Fas is crucial
for receptor activation. In this hypothesis, dissociation of one
Fab arm must occur in order to recruit more Fas monomers to
the receptor cluster and for agonism to be triggered
(Figure 5c). Antibodies with a very slow dissociation rate
would therefore be predicted to ‘lock’ two Fas monomers into
a non-signalling complex.
Discussion
The TNF receptor superfamily is a rich source of therapeutic
targets for agonistic monoclonal antibody approaches and yet
there is little knowledge of the molecular details of agonism or
strategies for improving agonist potency. The work described
hereused antibody-mediated Fasreceptor agonism, resulting
in cellular apoptosis, as a model system to explore these
questions.
The biochemical and structural comparison of epitopes
between Fas antibody E09 and the natural FasL, as well as
two commercially available antibody agonists, did not identify
asingle‘key’bindingsiteonthereceptor,whichcouldinitiatea
signalling cascade. The minimal predicted overlap between
the E09 epitope and that of FasL (Figure 2), suggested that
E09 was not functioning as a direct ligand mimetic. Indeed the
orientation of E09 binding was totally different, with the
antibody binding to the outside of the receptor complex and
FasL binding to the inside, when the receptor is viewed in the
expected trimeric conﬁguration (Figure 2). That both E09 and
FasL appeared to interact via a tyrosine side chain with an
arginine at residue 86 of Fas receptor did initially suggest that
Figure 5 Kinetic explanation of Fas agonist activity. Jurkat cells were incubated with the selected antibodies or FasL for the indicated time points. Agonistic activity was
monitored by caspase substrate z-DEVD cleavage. (a) Experiment performed without cross-linking the antibodies, showing the rate of caspase induction over time. Also
labelled next to the relevant curve is the rate of koff (s
 1) for each antibody, as determined by SPR. (b) The same experiment was performed following cross-linking of the
antibodies with protein A. These experiments were performed in triplicate and error bars indicate the S.D. between replicates. (c) Schematic illustration of the difference in
agonismbetweenanantibodywithrelativelyfastdissociationfromFas(above)andanantibodywithrelativelyslowdissociation(below).Theantibodywiththefasterrateofkoff
(above) is better able to recruit new Fas monomers and create an active signalling complex
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Cell Death and Differentiationthis could be a key interaction in the signalling process.
However, this tyrosine in the E09 VH CDR3 loop, could be
mutated to several other side chains without any major impact
onpotency(datanotshown),indicatingthatitwasnotacritical
residue for signal transduction.
Afﬁnity maturation of E09 was performed by directed
evolution and also by the rational approach of side chain
replacement to isolate antibodies with different afﬁnities for
Fas. This series of antibodies, when tested for agonistic
activity, showed a surprising inverse correlation between
afﬁnity and agonism. We believe this to be the ﬁrst
demonstration of an increase in antibody afﬁnity leading to a
decrease in biological potency, in contrast to the many
published examples of positive correlations between the two
attributes. Although the initial observation was a correlation
betweenhigher afﬁnity and reduced receptor agonism, further
analysisshowedaclearercorrelationbetweenaslowerrateof
dissociationandreducedagonism(Figure4b).Effectively,the
antibodieswiththeslowestdissociationrateswereimpairedin
both their maximal level of receptor agonism and the time
required to initiate signalling. As the E09 antibody was also
capable of antagonising the Fas:FasL interaction (Table 1),
we could also explore the correlation between afﬁnity and
antagonism using this series of antibodies. We would predict,
based on the many other antagonistic antibodies studied to
date, that we would see a direct correlation between afﬁnity
and antagonism.
The accumulated evidence led us to hypothesise a model
for agonism of receptors in the TNF receptor superfamily,
which takes into account that these receptors are normally
brought into an active trimeric conﬁguration by their naturally
trimeric ligands. The model predicts that bivalent agonists,
such as IgG antibodies, must be able to bind to Fas receptor
and then partially dissociate in order to free one Fab arm to
recruit further Fas monomers and form an active signalling
complex (Figure 5c). Antibodies with too slow a dissociation
rate would, in effect, become locked in a non-signalling,
dimeric state. Supporting this hypothesis are the previous
observations that the Fab arms of an antibody are capable of
considerable movement around the ﬂexible hinge region
23
and also that many receptors, including Fas,
24,25 are believed
to move freely within the plasma membrane in order to form
clusters for optimal signalling.
26
To test our hypothesis we used antibody cross-linking to
demonstrate that the impairment caused by slow dissociation
could be overcome in most cases by increasing the valency of
the agonist antibodies to avoid the non-signalling, dimeric
complexes (Figure 5 and Supplementary Figure 4). We show
that cross-linkedIgG and the trimeric FasLweremoreeffective
agonists than the standard bivalent IgG molecule (Figure 5).
Others have also shown that the higher valency IgM format of
the Fas agonist CH-11
27 leads to very high potency. This
observationaboutvalencyhasledsome to pursue higherorder
multimers, such as Mega-FasL,
28 as potential therapeutic
agonists, notwithstanding the safety concerns.
Although many others have observed that higher valency
Fas agonists are more potent at triggering apoptosis,
20,22,27–29
and our data is in agreement with those studies, this is the
ﬁrst detailed analysis of the relationship of afﬁnity to potency.
By using antibodies of a single lineage, which only differ by a
few amino acids, we have maintained a constant epitope on
Fas while varying the antibody afﬁnity. We have shown that
lower-afﬁnity Fas antibodies can have higher potency, a
theory that has in fact been put forward in a previous
publication
29 and may have much in common with the ‘serial
triggering’ hypothesis for peptide-MHC activation of T-cell
receptors.
30
The main implication of our ﬁnding is that bivalent agonists
of receptors in the TNF receptor superfamily could have a
potency ceiling, which is not surmountable by the conven-
tional approach of afﬁnity maturation. In fact, as shown here,
afﬁnity maturation would tend to impair the antibody potency.
Alternative engineering strategies would be required to
overcome this limitation. One example of such engineering
would be to use bispeciﬁc antibody technology to engineer a
bivalent molecule in which one arm contained a high-afﬁnity
binding site toanchor the antibodyonto one Fasmolecule and
the other arm contained a low afﬁnity binding site to efﬁciently
recruit further Fas monomers. Additional engineering of the
IgG hinge region to maximise the Fab arm ﬂexibility could
further enhance agonism of such a molecule.
In summary we describe the ﬁrst detailed structural and
kineticanalysisofarelatedlineageofagonistmoleculestothe
Fas receptor, which has enabled us to better understand the
nature of bivalent agonist signalling in the TNF receptor
superfamily. We propose a model to explain the surprising
inverse correlation between antibody afﬁnity and potency and
use the implications of the model to make suggestions, which
are relevant to future drug discovery efforts on targets within
the TNF receptor superfamily.
Materials and Methods
Cell lines and reagents. Tumour cell lines HeLa (cervix epitheloid
carcinoma) and Jurkat (T-cell leukaemia) were obtained from ATCC (Manassas,
VA,USA)andweremaintainedinDMEMmedium(Gibco,Invitrogen,Carlsbad,CA,
USA) containing 10% fetal bovine serum (Invitrogen) and 1% non-essential amino
acids (Invitrogen) or RPMI medium 1640 with GlutaMAX (Invitrogen) supplemented
with 10% fetal bovine serum, respectively. Commercial mouse anti-human Fas
antibodies ZB4 and CH-11 are from Upstate (Millipore, Billerica, MA, USA) and
SM1.1 from Chemicon (Millipore). DX2 antibody and human Fas ligand (hFasL)
were purchased from R&D Systems (Minneapolis, MN, USA). Human Fas receptor
in fusion with an Fc fragment and hFasL are from R&D Systems. The monomeric
format of the Fas ECD for Biacore and crystallisation studies was obtained from
Peprotech (Rocky Hill, NJ, USA).
Antibody isolation. Phage-display technology was used to isolate scFv
antibodies to the recombinant ECD of Fas receptor. A large non-immunised human
scFv phage-display library containing up to 10
11 binding members
12 was used for
antibody isolation as described previously.
31 Brieﬂy, human Fas receptor ECD in
fusion with an Fc fragment was immobilised overnight at 41C onto MaxiSorp plates
(Nunc, ThermoFisher, Waltham, MA, USA) at 10mg/ml in PBS before presentation
to theantibodylibrary.Solubleselectionswereperformedas describedpreviously
32
using biotinylated Fas receptor ECD/Fc protein and magnetic streptavidin beads
(Dynal, Invitrogen) for capturing the antigen-antibody complex.
Threetofourroundsofselectionwereperformedafteradeselectionstepusinga
large excess of the irrelevant human IgG1 antibody CAT002 to minimise the enrichment
of anti-Fcantibodies.Speciﬁcityto Fas receptor ECDwas conﬁrmedby phage-scFv
ELISAs as described in Vaughan et al.,
31 using CAT002 as irrelevant control.
Expression of scFv and IgG1 antibodies. Escherichia coli periplasmic
extracts were prepared in 96-well plate as previously described.
31 ScFv expression
was induced overnight with 20mM ﬁnal of IPTG and bacterial pellets were
resuspended the following day in cold TES buffer before centrifugation to clarify the
extract from cellular debris. ScFv were puriﬁed from bacterial periplasmic extract by
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PBS as described in Ruter et al.
8 Protein concentrations were determined by
bicinchoninic acid assay (Sigma-Aldrich, St. Louis, MO, USA). For IgG expression,
the VH and VL chains of selected antibodies were cloned into human IgG1
expression vectors as described in Persic et al.
33 except that an oriP fragment was
included in the vectors to facilitate use with human embryonic kidney Epstein–Barr
virus-encoded nuclear antigen-293 (HEK EBNA-293) cells and to allow episomal
replication. Co-transfection of the heavy chain vector pEU15.1 and lambda light
chain vector pEU4.4 into HEK EBNA-293 allowed whole IgG to be expressed and
puriﬁed by protein A afﬁnity chromatography (GE Healthcare, Little Chalfont, UK).
Human IgG1 concentration was determined spectrophotometrically using an
extinction coefﬁcient based on the amino-acid sequence of the antibody.
Kinetic and afﬁnity measurement by Biacore analysis. The afﬁnity
and kinetic parameters of anti-Fas antibodies for the human Fas receptor were
determined by SPR using a BIAcore 2000 instrument set up at 251C. For scFv
analysis,proteinG’(Sigma-Aldrich)immobilisedonaCM5sensorchipbytheamine
coupling method was used to capture 300–400 RUs of Fc-tagged recombinant
human Fas. Serial dilution of scFv from 200nM to 6.25nM in HBS-EP buffer
(Biacore, Uppsala, Sweden) with 0.1% BSA were injected at 30ml/min for 2min.
Dissociation was analysed for a short time to minimise avidity effect of potential
dimeric scFv. IgG analysis was performed by ﬁrst capturing B1000 RUs of the
antibody on the protein G’ – CM5 sensor chip and running a serial dilution from 400
to 12.5nM of monomeric human Fas ECD (Peprotech) as analyte for 1min
association followed by a 10-min dissociation phase. Curve ﬁtting was done on the
BIAevaluation 3.2 RC1 software (Biacore) using a 1:1 Langmuir binding model.
Biochemical competition assays. Biochemical ligand and epitope
competition assays were performed by immobilising anti-Fas E09 human IgG1 or
FasL onto MaxiSorp plates (Nunc) at 5 or 2.5mg/ml, respectively. After blocking,
serialdilutionsofanti-FasIgGorirrelevantCAT002wereaddedtothecoatedplates
in competition with biotinylated human Fas receptor Fc fusion protein at a ﬁnal
concentration of 0.5mg/ml or 0.75mg/ml for E09 and FasL competition assays,
respectively. Biotinylated Fas receptor bound to the plate was detected using
europium-labelled streptavidin (Perkin Elmer, Waltham, MA, USA) by measuring
ﬂuorescence at 340nm excitation and 615nm emission.
DNA fragmentation assay. Jurkat cells were seeded onto 96-well tissue
culture plates the day before the assay at a density of 2 10
3 cells per well in 90ml
mediaandgrownovernightat371Cand5%.CO2.Afteradding10mlofanti-FasIgGor
FasLat differentconcentrations,cellswerefurtherincubatedfor8hbeforedetermining
the level of DNA fragmentation using the Cell Death Detection ELISA
PLUS (Roche,
Indianapolis, IN, USA) according to the manufacturer’s instructions. Brieﬂy, cells were
pelleted and lysed for 30minat room temperature.Lysates were centrifuged and 20ml
of supernatant transferred to a streptavidin coated plate before adding 80mlo f
immunoreagents for the sandwich ELISA containing a biotinylated anti-histone and a
peroxidase-conjugated anti-DNA antibodies. Plates were incubated for 2h at room
temperature before adding the peroxidase detection reagents and reading on a Wallac
(Perkin Elmer) 1420 workstation at 405nm.
Caspaseassay. Jurkatcellswereseededonto96-welltissuecultureplatesthe
day before the assay at a density of 1 10
4 cells per well in 90ml media and grown
overnight at 371C and 5%. CO2. For titration experiments, cells were incubated for
8h after addition of 10ml of IgG or FasL at different concentrations before adding
the caspase assay reagent.
Kinetic activation experiments were performed at a concentration of 5nM ﬁnal of
IgGandFasLor1nMofIgMCH-11inorderto maintainthemolarityof Fasreceptor
binding molecules. For cross-linking experiment, IgGs at 50nM were incubated
overnight at 41C with 12.5nM of recombinant protein A (Pierce, ThermoFisher) to
pre-form the complex before adding 10ml to the cells. Activity assay was performed
using a Caspase-Glo 3/7 assay kit (Promega, Madison, WI, USA) according to the
manufacturer’s instructions and plates were incubated for 1h at room temperature
before reading on a luminometer.
Cell-viability assay. Tumour cells were seeded in culture medium onto 96-
well tissue culture plates at a density of 3 10
4 cells/well or 2 10
4 cells/well in
100ml for HeLa and Jurkat cell lines, respectively. Periplasmic extract of anti-Fas
scFv were added to HeLa cells in combination with a sub-lethal dose of
cycloheximide (Sigma-Aldrich) at 6.6mg/ml ﬁnal as sensitising agent. Titration
experiments were performed by adding 15ml of a serial dilution of FasL or IgG in
PBS plus 35ml of medium supplemented with penicillin and streptomycin to Jurkat
cells. Cyclohemixide sensitisation was not required for that cell line to obtain Fas-
mediated cell killing. For cross-linking experiment, IgG-Protein A complexes were
pre-formedbyincubating0.1mg/mlofantibodywith170nMofProteinA(4:1molar
ratio) before the serial dilution. After 16–18h incubation at 371C and 5% CO2,
Alamar Blue (Serotec, Oxford, UK) was added in an amount equal to 10% of the
culture volume. The plates were returned to the incubator for an additional 7h at
371CandviabilityassessedbymeasuringﬂuorescenceonaWallac1420workstation
at 560nm excitation and 590nm emission. Data were analysed by using PRISM
software (GraphPad, La Jolla, CA, USA).
Ribosome-displayafﬁnitymaturation. The gene encodingthe E09 anti-
Fas scFv was used as the template for constructing the randomised library. Error-
pronePCR was performed as described
21 using Taqpolymerasein the presenceof
7mM MgCl2 and 0.3mM MnCl2 to introduce an average of 4.5 base changes per
scFv gene. Ribosome-display selections were performed in a soluble format as
previously described
34 using human Fas-Fc protein and capturing the antigen-scFv
complexes, thanks to Protein G-coated magnetic beads (Dynal). Stringent
selections for higher-afﬁnity scFv variants were applied according to previously
published principles,
32 whereby the concentration of antigen was reduced over
successive rounds of selection from 50nM in round 1 down to 20pM in round 6.
Afﬁnity maturation screening assays. Screening assays were
essentially performed as described.
21 Primary screening was performed by
immobilising supernatant-leaked scFv onto high binding COSTAR (Corning, NY,
USA) plates. Binding of human Fas receptor Fc fusion protein incubated in skimmed-
milk blocked plates at 0.35ng/ml were detected using 0.5mg/ml of europium-labelled
anti-human IgG (Perkin Elmer). Fluorescence signals detected at 340nm excitation
and 615nm emission were normalised by the cell-culture density at 600nm to take
into account difference in cell growth. Conﬁrmatory assay was based on a surrogate
afﬁnity screen using the same principle as the primary assay. Puriﬁed scFvs were
immobilised on COSTAR plate and incubated for 2h with a serial dilution of human
FasreceptorFcfusionproteinbeforedetectionwiththeeuropium-labelledanti-human
IgG. Surrogate afﬁnity of the scFvs for Fas receptor was calculated from the
equilibrium binding titrations using PRISM software (GraphPad).
Point mutagenesis. Single-point mutants of E09 scFv were generated by
saturation mutagenesis targeting the following six contact residues (numbered
according to Kabat
35): VH52 Ala, VH52a Tyr, VH52b Arg, VH55 Gly, VH56 Ser or
VH58 Tyr. Site-directed mutagenesis has been performed using a classic molecular
biology approach based on PCR with the following mutagenic primers:
4E09_NSS_A52_fwd
50-GGGTTGGCAGTATCNSSTATAGGGGGAATAGCAATAGTGG-30
4E09_NSS_Y52a_ fwd
50-GGGTTGGCAGTATCGCCNSSAGGGGGAATAGCAATAGTGG-30
4E09_NSS_R52b_ fwd
50-GGGTTGGCAGTATCGCCTATNSSGGGAATAGCAATAGTGG-30
4E09_NSS_G55_ fwd
50-GGGGAATAGCAATAGTNSSAGCACCTACTATAATCCGTCCCTCAAG-30
4E09_NSS_S56_ fwd
50-GGGGAATAGCAATAGTGGGNSSACCTACTATAATCCGTCCCTCAAG-30
4E09_NSS_Y58_ fwd
50-GGGGAATAGCAATAGTGGGAGCACCNSSTATAATCCGTCCCTCAAG-30
After cloning in the pCANTAB6 vector,
31 ligations were transformed in E. coli
TG1 strain. Mutants were identiﬁed by sequencing, and a total of 32 clones were
selected for scFv puriﬁcation and afﬁnity characterisation.
Production of E09 and EP6b_B01 Fabs for crystallisation.
Anti-Fas E09 human IgG1 was transiently expressed in EBNA-293 and puriﬁed by
protein A chromatography using MabSelect SuRe (GE Healthcare). Puriﬁed IgG was
digested by papain (Sigma-Aldrich) at a ratio of 1mg enzyme per 100mg of antibody
for 5h at room temperature in 30nM DL-cysteine buffer. Digestion was stopped by
adding iodoacetamide at a ﬁnal concentration of 50mM. Fab fragment was then
puriﬁed on MabSelect SuRe column in a non-binding mode followed by a gel-ﬁltration
step on Superdex 75 (GE Healthcare) in 50mM acetate pH 5.5 buffer containing
100mM NaCl. At the end of the process, 1.45ml of puriﬁed Fab at 5.48mg/ml was
obtained. Binding activity of the E09 Fab fragment was shown to be similar to the
human IgG1 by Biacore analysis using a CM5-Protein G’ chip to capture human Fas
receptor –Fcfusionproteinandrunningaserialdilutionof theFabfragment as analyte.
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tag in CHO cells. The Fab was puriﬁed by immobilised metal afﬁnity chromatography
using HisTrap (GE Healthcare) and by size exclusion chromatography in PBS
Crystallisation and structure determination. Excess Fab was mixed
with the ECD of human Fas and incubated on ice. The excess protein was separated
from the complex by gel ﬁltration using a Superdex 200 10/300 GL (GE Healthcare) in
50mMMES/NaOH,pH6.5,100mMNaCl.Thecomplexeswereconcentratedto11mg/
ml and crystallised by sitting drop vapour diffusion at 41C. The E09-Fas complex
crystallised in 100mM Tris/HOAc, pH 8.5, 5mM CdCl2, 20% PEG4000, whereas the
EP6b_B01-Fas complex crystallised in 100mM HEPES/NaOH, pH 7.5, 10%
isopropanol, 20% PEG4000. For data collection the crystals were cryo-protected in a
mother liquor solution containing additional 20% ethylene glycol and prefrozen in liquid
propane (E09) or nitrogen (EP6b_B01). Diffraction data of the E09-Fas and EP6b_B01-
Fas complexes were collected on a Pilatus detector at the Swiss Light Source (Villigen,
Switzerland) using a wavelength of 0.9000 and 1.0000A ˚, respectively. Data were
processed using XDS
36 and the phases solved by molecular replacement using Phaser
v1.3(E09)andv2.1.4(EP6b_B01).
37ForthephasesolutionoftheﬁrstFab:Fasstructure
(E09) an iterative process involving the four domains of the antibody HC19 (1GIG) was
applied.
38 The obtained solution was reﬁned with Phenix before the molecular
replacement was ﬁnished by searching the Fas receptor using a polyserine model of the
DR5 structure 2H9G.
20
The model was automatically built with ARP/wARP v7
39 and rebuilt in Coot
v0.3.3.
40 Reﬁnement of both complexes was carried out using Phenix v1.6.4 and
Coot v0.6.1.
41 Data collection and reﬁnement statistics of the two structures are
listed in Supplementary Table 1.
The atomic coordinatesand structure factors have been deposited in the Protein
Data Bank with accession number 3TJE for the E09:Fas complex and 3THM for the
EP6b_B01 complex.
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